Navigation Links
New medications show promise in treating drug-resistant prostate cancer
Date:4/7/2009

e mice," said Sawyers. "While treating these animals with bicalutamide produced a modest effect on their tumors, the new drugs caused the tumors to shrink dramatically, and in some animals almost completely," he said.

Sawyers said the new drugs bind tightly enough to the natural hormone-binding site on androgen receptors to prevent most of them from functioning even in cells with a lot of androgen receptors. Bicalutamide interferes with the receptor through a different mechanism, which backfires, when too much androgen receptor is present, Sawyers explained.

The promising laboratory studies led Medivation to license the drugs for commercial development, said Sawyers, who serves as a consultant to the company and would receive royalties on the drug should it prove to be successful.

The company chose to use MDV3100 for clinical studies, which began in 2007. In those initial studies, 30 men with antiandrogen-resistant prostate cancer received low doses of MDV3100. Twenty-two of those men showed a sustained decline in their blood levels of prostate specific antigen (PSA), an indication that their cancer was responding favorably to the drug. This trial is still under way, and results from a total of 140 patients receiving higher doses of the drug will be reported within the next year, said Sawyers.

Medivation has received permission from the Food and Drug Administration for a large clinical trial of MDV3100 on about 1,200 patients with antiandrogen-resistant disease. This study will assess MDV3100's effect on cancer survival and will take several years.

While these preliminary results are promising, Sawyers said his laboratory will continue to seek further improvements in drug therapy for prostate cancer. "There were some men in the initial trial in which the drug didn't work at all, and we want to find out why," he said. "It may be because the drug is not potent enough to overcome resistance due to androgen receptor overexpression. Or, it may b
'/>"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Device prevents potential errors in childrens medications
2. Study of successful drug targets could hasten development of new medications
3. Genetic variant mimics effect of heart failure medications
4. Hypertension and cholesterol medications present in water released into the St. Lawrence River
5. Innovative civil engineering application promises cleaner waters
6. New CPR promises better results by compressing abdomen, not Chest
7. Tiny tubes and rods show promise as catalysts, sunscreen
8. New genetic research into nicotine addiction shows promise for personalized treatment
9. Genetic ancestral testing cannot deliver on its promise, study warns
10. Sweet potato shines as new promise for small enterprise and hunger relief in developing countries
11. Summer-dormant tall fescue grass shows promise for pasture improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... In the search for medication against Alzheimer,s disease, scientists have ... break down Amyloid beta (A-beta). After all, it is the ... brains of Alzheimer,s patients. Starting point for the formation of ... were the first to unravel the function of APPL ... healthy fruit flies. , Alessia Soldano (VIB/KU Leuven): "We ...
(Date:5/23/2013)... Northwest National Laboratory honored more than 165 staff ... property at PNNL,s annual Intellectual Property Commercialization Recognition ... of Energy national laboratory named materials scientist Jun ... developing battery materials that can store large amounts ... and reduce the time it takes to charge ...
(Date:5/23/2013)... of genomic DNA around nucleosomes in the cell ... team of Ludwig-Maximilians-Universitaet (LMU) in Munich now describes ... locally displaced from nucleosomes for transcription. , In ... the cell nucleus, wrapped around disk-shaped particles called ... different histone proteins and accommodating two loops of ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Biochemistry: Unspooling DNA from nucleosomal disks 2
... A new study has found that protein and not ... and burning calories. The research, published in the ... , has implications for understanding obesity and sleep disorders. ... which secrete a stimulant called orexin/hypocretin in the brain. ...
... that fuel is present in all vegetative matter that ... day grow their own fuel. Last year, global biofuel ... for 2.7% of the world,s transportation fuel. Bioethanol, a ... food crops such as corn and sugarcane. However, technologies ...
... extinction is a complicated task, especially for species that migrate ... Georgia and Tulane University have developed a mathematical model that ... the early online edition of the Royal Society journal ... lot of species, we don,t know very much about their ...
Cached Biology News:3 p.m. slump? Why a sugar rush may not be the answer 2Toward more cost-effective production of biofuels from plant lignocellulosic biomass 2New model more accurately describes migratory animals' extinction risk 2
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics ... company developing DCVax ® personalized immune therapies for ... its exhibit at this year,s American Society Of Clinical ... to highlight its leadership role in immune therapy.  ... ASCO annual meeting is the pre-eminent conference focused on ...
(Date:5/23/2013)... 23, 2013  Verenium Corporation (Nasdaq: VRNM ... development and commercialization of high-performance enzymes, today announced that ... will present at two upcoming conferences. (Logo: ... at the Second Annual Marcum LLP Microcap Conference on ... in New York City.  The presentation is scheduled to ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... Pier Pharmaceuticals Inc.(formerly known as Steady Sleep Rx ... treatment of sleep related breathing disorders (SRBDs), announced today ... CEO & President and his election to the Board ... Letendre will be responsible for spearheading the clinical, regulatory, ...
... Nanotecnologia (ICN), in Barcelona, has demonstrated a device that induces ... in developing the spin computers of the future. The results ... Science. The authors are Marius V. Costache and Sergio O. ... and Engineering of Nanodevices Group at ICN. Spintronics is ...
... 2010 The new biotechnology curriculum at Bunker Hill ... state to win a Silver endorsement from the new ... the College,s program acknowledges that it is successfully training ... state to keep a competitive edge. To ...
Cached Biology Technology:Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director 2A 'spin ratchet': A new electronic structure for generating spin current 2Bunker Hill Community College Wins Major Endorsement for Biotechnology Courses 2
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... raised against a partial recombinant ... TOPORS (NP_005793, 98 a.a. ... protein with GST tag. ... NM_005802 Protein ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
... antibody raised against a partial recombinant NFKBIB. ... ~ 145 a.a) partial recombinant protein with GST ... Accession: BC015528 ... OMIM: 604495, GeneID: ...
Biology Products: